Purple Biotech Ltd reaches 20-day high amid sector rotation.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 10 2025
0mins
Source: DRS
Purple Biotech Ltd experienced a significant price increase of 16.26%, reaching a 20-day high. This movement occurs in the context of a broader market decline, with the Nasdaq-100 down 0.65% and the S&P 500 down 0.41%.
This surge comes amid sector rotation as investors shift their focus towards biotech stocks, despite the overall market weakness. The stock's performance indicates a strong interest in the sector, potentially driven by recent developments in drug trials and innovations within the industry.
The implications of this price movement suggest that Purple Biotech Ltd is gaining traction among investors, reflecting confidence in its future prospects. As the market continues to fluctuate, the company's ability to maintain this momentum will be crucial for its long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PPBT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PPBT
Wall Street analysts forecast PPBT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.590
Low
34.00
Averages
34.00
High
34.00
Current: 1.590
Low
34.00
Averages
34.00
High
34.00
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Purple Biotech's IM1240 Study Advances with Promising Results
- Extended Half-Life: IM1240 demonstrated an 8-fold longer half-life and 16-fold greater systemic exposure in a non-human primate toxicology study, indicating significant potential for enhanced anti-cancer efficacy and laying the groundwork for future clinical trials.
- Validated Anti-Tumor Activity: The drug exhibited anti-tumor activity across PD-1 and chemotherapy-resistant patient-derived tumor samples, particularly in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a crucial contributor to its efficacy, highlighting its potential in treating resistant tumors.
- Induction of Immune Structures: IM1240 induced mature tertiary lymphoid structures in non-small cell lung cancer patient-derived explants, increasing CD8 T and NK cell abundance while reducing regulatory T cells, suggesting a favorable prognosis and enhanced anti-tumor immune response for patients.
- Improved Safety Profile: Compared to the non-capped variant IM1222, IM1240 showed significantly reduced cytokine release in NHPs, with minimal IL-6 and TNF-α at a 10 mg/kg dose, indicating a better safety and tolerability profile for clinical applications.
See More
Purple Biotech Reports Q1 2026 Financial Results
- Financial Overview: Purple Biotech reported a GAAP EPS of -$0.09 for Q1 2026, indicating ongoing challenges in profitability, which may lead to cautious market sentiment regarding its future prospects.
- Adjusted Net Loss: The adjusted net loss for the three months ended March 31, 2026, was $2.1 million, an increase of $0.8 million compared to $1.3 million in the same period of 2025, reflecting pressures on cost control and revenue growth that could impact investor confidence.
- Cash Position: As of March 31, 2026, Purple Biotech had cash and cash equivalents totaling $6.4 million, which is expected to provide a cash runway into 2027, ensuring continued investment in R&D and market initiatives.
- Non-GAAP EPS: The company reported a non-GAAP EPS of $19.85, which, while potentially attracting investor interest, contrasts sharply with GAAP figures, highlighting discrepancies in financial transparency and profitability that could affect long-term stock performance.
See More
PURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM
New Advisory Board Established: Purple Biotech Ltd has formed a scientific advisory board for its CAPT-N-3 antibody platform.
Focus on Antibody Development: The board will provide expertise and guidance to enhance the development of the CAPT-N-3 antibody platform.
See More
Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.
See More
Purple Biotech Regains Nasdaq Compliance
- Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
- Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
- Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
- Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.
See More
Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses
- Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
- Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
- Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
- Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.
See More
Purple Biotech's IM1240 Study Advances with Promising Results
- Extended Half-Life: IM1240 demonstrated an 8-fold longer half-life and 16-fold greater systemic exposure in a non-human primate toxicology study, indicating significant potential for enhanced anti-cancer efficacy and laying the groundwork for future clinical trials.
- Validated Anti-Tumor Activity: The drug exhibited anti-tumor activity across PD-1 and chemotherapy-resistant patient-derived tumor samples, particularly in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a crucial contributor to its efficacy, highlighting its potential in treating resistant tumors.
- Induction of Immune Structures: IM1240 induced mature tertiary lymphoid structures in non-small cell lung cancer patient-derived explants, increasing CD8 T and NK cell abundance while reducing regulatory T cells, suggesting a favorable prognosis and enhanced anti-tumor immune response for patients.
- Improved Safety Profile: Compared to the non-capped variant IM1222, IM1240 showed significantly reduced cytokine release in NHPs, with minimal IL-6 and TNF-α at a 10 mg/kg dose, indicating a better safety and tolerability profile for clinical applications.
See More
Purple Biotech Reports Q1 2026 Financial Results
- Financial Overview: Purple Biotech reported a GAAP EPS of -$0.09 for Q1 2026, indicating ongoing challenges in profitability, which may lead to cautious market sentiment regarding its future prospects.
- Adjusted Net Loss: The adjusted net loss for the three months ended March 31, 2026, was $2.1 million, an increase of $0.8 million compared to $1.3 million in the same period of 2025, reflecting pressures on cost control and revenue growth that could impact investor confidence.
- Cash Position: As of March 31, 2026, Purple Biotech had cash and cash equivalents totaling $6.4 million, which is expected to provide a cash runway into 2027, ensuring continued investment in R&D and market initiatives.
- Non-GAAP EPS: The company reported a non-GAAP EPS of $19.85, which, while potentially attracting investor interest, contrasts sharply with GAAP figures, highlighting discrepancies in financial transparency and profitability that could affect long-term stock performance.
See More
PURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM
New Advisory Board Established: Purple Biotech Ltd has formed a scientific advisory board for its CAPT-N-3 antibody platform.
Focus on Antibody Development: The board will provide expertise and guidance to enhance the development of the CAPT-N-3 antibody platform.
See More
Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.
See More
Purple Biotech Regains Nasdaq Compliance
- Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
- Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
- Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
- Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.
See More
Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses
- Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
- Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
- Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
- Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.
See More
